Carbamazepine versus phenytoin monotherapy for epilepsy: An individual participant data review

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Nolan, Sarah J ^a   Marson, Anthony G ^a   Weston, Jennifer ^a   Tudur Smith, Catrin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; ANTICONVULSIVE AGENT;

ABDOMINAL PAIN; ACNE; ATAXIA; BODY DYSMORPHIC DISORDER; CLINICAL EFFECTIVENESS; COORDINATION DISORDER; DEPRESSION; DISEASE CLASSIFICATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HIRSUTISM; HUMAN; IMPOTENCE; LIBIDO DISORDER; MEMORY DISORDER; MONOTHERAPY; NAUSEA AND VOMITING; NYSTAGMUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; TREMOR; ADULT; CHILD; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; INDUCTION CHEMOTHERAPY; META ANALYSIS; TREATMENT WITHDRAWAL;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; HUMANS; INDUCTION CHEMOTHERAPY; PHENYTOIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WITHHOLDING TREATMENT;

EID: 84991258763     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001911.pub2     Document Type: Review

References (91)

1. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1985;48(7):639-44.
2. Cereghino JJ, Brock JJ, Van Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology 1974;24(5):401-10.
3. Czapinski P, Terczynski A, Czapinska E. Randomised 36-month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia 1997;38 Suppl(3):42.
4. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13.
5. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine and Child Neurology 1991;33:524-34.
6. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry 1995;58(1):44-50.
7. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalized tonic-clonic seizures. New England Journal of Medicine 1985;313(3):145-51.
8. Miura H. Developmental and therapeutic pharmacology of antiepileptic drugs. The Japanese Journal of Psychiatry and Neurology 1993;47(2):169-74.
9. Ogunrin O, Adamolekun B, Ogunniyi A. Cognitive effects of anti-epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences 2005;24:18-24.
10. Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurologica Scandinavica 1994;89:81-6.
11. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983;33(7):904-10.
12. Ravi Sudhir RV, Sawhney IMS, Prabhakar S, Pershad D, Nain CK. Comparative cognitive effects of phenytoin and carbamazepine in adult epileptics. Neurology India 1995;43(4):186-92.
13. Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Research 1999;33(2-3):133-43.
14. Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine and Child Neurology 1993;35:149-57.
15. Berger JR, Ramsay RE, Wilder BJ, Bruni J. A double-blind study comparing carbamazepine to phenytoin as initial seizure therapy. Neurology 1981;31(4 Pt 2):159.
16. Bird CAK, Griffin BP, Miklaszewska JM, Galbraith AW. Tegretol (carbamazepine): a controlled trial of new anti-convulsant. British Journal of Psychiatry 1966;112:737-42.
17. Bittencourt PRM, Antoniuk SA, Bigarella MM, da Costa JC, Doro MP, Ferreira AS, et al. Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Research 1993;16:147-55.
18. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. British Journal of Clinical Practice 1983;27:7-9.
19. Canadian Study Group for Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998;39(9):952-9.
20. Cereghino JJ, Brock JT, White BG, Penry JK. Evaluation of carbamazepine in epileptic patients. Neurology 1973;23:433.
21. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27:1023-8.
22. Goggin T, Casey C, Callaghan N. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal 1986;79(6):150-6.
23. Hakami T, Todaro M, Petrovski S, MacGregor L, Velakoulis D, Tan M, et al. Substitution monotherapy with levetiracetam vs older antiepileptic drugs: A randomized comparative trial. Archives of Neurology 2012;69(12):1563-71.
24. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy and Behaviour 2003;4(6):659-66.
25. Kosteljanetz M, Christiansen J, Dam AM, Hansen BS, Pedersen H, Dam M. Carabamazepine vs phenytoin. A controlled clinical trial in focal motor and generalized epilepsy. Archives of Neurology 1979;36(1):22-4.
26. Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1993;31(2):61-5.
27. Martinez W, Kaminow L, Nanry KP, Hammer AE, Barrett PS. Evaluation of lamotrigine versus carbamazepine, phenytoin, or divalproex sodium as monotherapy for epilepsy patients who failed or could not tolerate previous antiepileptic drug therapy. Epilepsia 2000;41(Suppl 7):100.
28. Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia 1995;36(12):1195-202.
29. Rajotte P, Jilek W, Jilek L, Perales A, Giard N, Bordeleau J, et al. The anti-epileptic and psychotropic properties of carbamazepine (Tegretol) [Proprietes antiepileptiques et psychotropes de la carbamazepine (Tegretol)]. L'Union Med du Canada 1967;10:1200-6.
30. Sabers A, Moller A, Dam M, Smed A, Arlien-Soborg P, Buchman J, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurologica Scandinavica 1995;92(1):19-27.
31. Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The place of sodium valproate in the treatment of epilepsy. Royal Society of Medicine International Congress and Symposium No. 30. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7-16.
32. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. British Medical Journal 1978;1(6111):474-6.
33. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurologica Scandinavica Supplementum 1975;60:39-42.
34. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia 1976;17(2):169-76.
35. Troupin AS, Green JR, Halpern LM. Carbamazepine (Tegretol) as an anticonvulsant. A controlled double-blind comparison with diphenylhydantoin (Dilantin). Acta Neurologica Scandinavica Supplement 1975;75:13-26.
36. Troupin A, Ojemann LM, Halpern L, Dodrill C, Wilkus R, Friel P, et al. Carbamazepine: a double blind comparison with phenytoin. Neurology 1977;27(6):511-9.
37. Wilkus RJ, Dodrill CB, Troupin AS. Carbamazepine and the electroencephalogram of epileptics: a double blind study in comparison to phenytoin. Epilepsia 1978;19:283-91.
38. Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology and Neurosurgery 2010;112:291-5.
39. Rysz A. Effect of monotherapy with phenytoin or carbamazepine on somatosensory evoked potentials in patients with newly diagnosed epilepsy. Polski tygodnik lekarski 1994;49:79-81.
40. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502-6.
41. Carl GF, Smith ML. Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 1992;33(2):372-5.
42. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
43. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489-501.
44. Commission on Classification and Terminology of theInternational League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
45. ILAE commission on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7):799-803.
46. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology 1992;6(3):257-61.
47. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
48. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma aminobutyricacid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995;47:1189-96.
49. Gruber CM, Brock JT, Dyken MD. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, dipheylhydantoin, ethotoin, metharbital, and methylphenylhydantion in motor seizures. Clinical Pharmacology and Therapeutics 1962;3:23-8.
50. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935-1984. Epilepsia 1993;34:453-68.
51. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
52. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007;68:326-37.
54. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-120.
55. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9.
56. Juul-Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24:297-312.
57. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
58. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342:314-9.
59. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026-8.
61. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWA, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48:833-41.
62. Malfosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.
63. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030]
64. Matlow J, Koren G. Is carbamazepine safe to take during pregnancy?. Candian Family Physician 2012;58:163-4.
65. Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
66. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009;339:2535.
67. Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry 2006;77(2):193-8.
68. Murray CJL, Lopez AD. Global Comparative Assessments in the Health Sector. Geneva: World Health Organization, 1994.
69. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90.
70. National Institute for Health and Care Excellence. The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care. London: National Institute for Health and Care Excellence; Clinical Guidance 137, 2012.
71. Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health. Quebec City, 2013:114-5.
72. Nolan SJ, Marson AG, Pulman J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD001769.pub2]
73. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics 1997;68(1):18-24.
74. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4:627-34.
75. Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23.
76. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival end-points. Statistics in Medicine 1998;17:2815-34.
77. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage dependent inhibition of type hA Nai channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology 1991;40:756-65.
78. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433-43.
79. Sander JW. The use of anti-epileptic drugs - Principles and practice. Epilepsia 2004;45(6):28-34.
80. Scheinfeld N. Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatology Online Journal 2003;9(3):6.
81. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-9.
82. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985;313(15):916-21.
83. StataCorp . Stata Statistical Software: Release 11. CollegeStation, TX: StataCorp LP, 2009.
84. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49(2):542-6.
85. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34.
86. Wallace H, Shorvon SD, Hopkins A, O'Donoghue M. National Society of Epilepsy Guidelines. London: Royal College of Physicians, 1997.
87. Wilder BJ. Phenytoin: clinical use. Antiepileptic Drugs. 4th Edition. New York: Raven Press, 1995:339-44.
88. Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(11):3357-51.
89. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenyihydantoin and carbamazepine on voltage sensitive sodium channels in neuroblastoma cells. Molecular Pharmacology 1985;27:549-58.
90. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001911]
91. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001911]